Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: Nivolumab and Ipilimumab in CDK12-mutated Cancers
NCT03570619Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in metastatic castration-resistant prostate cancer (mCRPC), solid tumor, sponsored by University of Michigan Rogel Cancer Center. Started Dec 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)solid tumor
Beyond the preview
Go deeper on NCT03570619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570619.